Q2 2025 Earnings Call Transcript August 4, 2025 Axsome Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.92 ...

Key Points Shopify's moat and vast runway for growth make its prospects highly attractive. Axsome Therapeutics has a robust late-stage pipeline that should lead to important approvals.10 stocks we ...

Axsome Therapeutics expects the completion of its ongoing late-stage clinical trial for Auvelity in AD to complete in the first half of 2024. So it won't hit the market until early 2025 at best.

In the assessment of 12-month price targets, analysts unveil insights for Axsome Therapeutics, presenting an average target ...

Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m, up 81% YoY, but net loss increased to $(64.6m). Despite positive market response and promising pipeline candidates ...

Last month we discussed that Axsome Therapeutics stock is likely to continue to see higher levels after it rose 6% in a week following the U.S. FDA’s acceptance of a new drug application for the ...

Shares of Axsome Therapeutics have posted a 30% gain so far in 2022. There's a sizeable niche and unmet need in the MDD market that Auvelity could address (novel MOA for patients who don't respond ...

Greetings, and welcome to the Axsome Therapeutics first-quarter 2025 conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to ...

Axsome shares beat the bear market last year. Axsome Therapeutics (AXSM 0.21%) was one of last year's hottest stocks. It climbed more than 100% and beat the bear market.

Axsome Contact:Mark Jacobson Chief Operating Officer Axsome Therapeutics, Inc.22 Cortlandt Street, 16th Floor New York, NY 10007Tel: 212-332-3243Email: mjacobson@axsome.com www.axsome.com References ...

Axsome Therapeutics Inc (NASDAQ: AXSM) shares are trading higher by 3.22% to $63.02 Monday morning after the company reported mixed fourth-quarter financial results. What Happened?

Axsome Therapeutics stock declined 2.9% over a five-day trading period ending 6/17/2021, compared to a broader market (S&P500) decline of 0.2% ...